Pancreatic cancer is the fourth-leading cause of cancer-related death in the United States (1) . Among individuals who develop pancreatic adenocarcinoma, only 5% will survive five years after diagnosis, and most patients live for less than 12 months (2) . A better understanding of predisposing factors is greatly needed to improve outcomes for patients with this highly lethal malignancy.
The risk of pancreatic cancer is increased among individuals with glucose intolerance, including those with excess weight (3) (4) (5) , diabetes mellitus (6) , and high serum glucose (7) (8) (9) . Nevertheless, this increased risk with high glucose levels may be due to consequences of hyperinsulinemia, abnormal pancreatic β-cell function, hyperglycemia itself, or a combination of these (9) (10) (11) (12) . Furthermore, concern remains that observed glucose intolerance may be the result of subclinical cancer, rather than an etiologic factor (13) .
Hemoglobin A1c (HbA1c) reflects an individual's mean plasma glucose over approximately the preceding three months and therefore is a direct measure of chronic glucose exposure.
The American Diabetes Association (14) and International Expert Committee (15) have advocated measurement of HbA1c as the preferred approach to the diagnosis and management of hyperglycemia and diabetes mellitus, rather than fasting or postload plasma glucose. The favorable features of HbA1c cited by these groups include stability after collection, low within-individual variability, and no preparation necessary prior to measurement, such as with an overnight fast or ingestion of an oral glucose load. However, measurement of HbA1c does not provide information on the relative contributions of peripheral insulin resistance and pancreatic β-cell dysfunction to hyperglycemia.
In secretory granules within pancreatic β-cells, proinsulin is cleaved to liberate insulin for secretion into circulation. A proportion of proinsulin molecules remain uncleaved when granules fuse with the β-cell membrane, such that proinsulin also enters the circulation. However, with insulin resistance and pancreatic β-cell dysfunction, circulating insulin, proinsulin, and the ratio of proinsulin to insulin are altered (16) . Notably, production of insulin and proinsulin increase with increasing insulin resistance to compensate for impaired peripheral insulin signaling (10) . In contrast, the proinsulin to insulin ratio is relatively stable in states of peripheral insulin resistance, but increases as pancreatic β-cell secretory capacity declines, due to impaired insulin processing by the β-cell mass (17) (18) (19) . In sum, disproportionate elevation in circulating proinsulin compared to insulin acts as a marker of impaired β-cell function, while elevated circulating insulin and proinsulin mark peripheral insulin resistance.
To prospectively evaluate markers of glycemia, peripheral insulin resistance, and impaired β-cell function in relation to pancreatic cancer risk, we measured circulating prediagnostic HbA1c, insulin, proinsulin, and proinsulin to insulin ratio among male and female participants from five large, US cohort studies with plasma samples collected prior to cancer diagnosis. To address the issue of preclinical cancer leading to glucose intolerance, we performed analyses with exclusion of case patients diagnosed within two, five, or 10 years of blood collection.
Methods

Study Population
Our study population included patients with pancreatic cancer and control subjects from five prospective studies: Health Professionals Follow-up Study (HPFS), Nurses' Health Study (NHS), Physicians' Health Study (PHS), Women's Health Initiative-Observational Study (WHI-OS), and Women's Health Study (WHS). HPFS was initiated in 1986 when 51 529 US men aged 40-75 years working in health professions completed a mailed questionnaire (20) . NHS was initiated in 1976 when 121 700 female nurses aged 30-55 years completed a mailed questionnaire (21) . Participants have responded to biennial questionnaires. PHS is a completed trial initiated in 1982 of aspirin and β-carotene among 22 071 male physicians, aged 40-84 years. After trial completion, participants were followed as an observational cohort (22) . WHI-OS consists of 93 676 postmenopausal women, aged 50-79 years, enrolled 1994-1998 at 40 US clinical centers (23, 24) . Participants completed a baseline clinic visit and annual mailed questionnaires. WHS is a completed trial initiated in 1992 of aspirin and vitamin E among 39 876 female health professionals aged ≥45 years. After trial closure, 88% of participants continued as an observational cohort (25) . The current study was approved by the Human Research Committee at Brigham and Women's Hospital, Boston, MA, and participants provided informed consent.
We included incident pancreatic adenocarcinoma cases diagnosed through 2008 with available plasma and no prior cancer except nonmelanoma skin cancer. Control subjects were alive without cancer at the case patient's diagnosis and provided blood samples. We randomly selected two or three control subjects per case patient, matching by cohort (also matches by sex), year of birth (±5 years), smoking status (never, past, current, missing), and fasting status (<8 hours, ≥8 hours).
Case patients were identified by self-report or death follow-up. Deaths were ascertained from next of kin, postal service, or National Death Index; this method captures greater than 98% of deaths (26) . Medical records were reviewed by physicians blinded to exposure data. The initial dataset included 478 case patients and 1075 control subjects. We excluded 122 participants who reported a diabetes history at blood collection (29 case patients, 38 control subjects, and 55 control subjects matched to excluded case patients). For insulin, the assay failed for 2 case patients and 1 control subject. For proinsulin, the assay failed for 1 case patient and 3 control subjects. Stored red cells were available for HbA1c measurement in 428 case patients and 927 control subjects. Covariates were obtained from baseline questionnaires in PHS, WHI, and WHS and questionnaires prior to blood draw in HPFS and NHS, as described previously (27) . HbA1c was assayed by the laboratory of Dr Nader Rifai (Children's Hospital, Boston, MA) using reagents from Roche Diagnostics (Indianapolis, IN). Plasma insulin and proinsulin were assayed by the laboratory of Dr Michael Pollak (McGill University, Montreal, Canada). To calculate the proinsulin to insulin ratio, we multiplied insulin measurements by 6.945 to convert units to pM (1 µIU/mL = 6.945 pM) and then divided proinsulin by insulin. Plasma insulin was measured in two batches. The first batch included 140 case patients and 243 control subjects, using reagents from Diagnostic Systems Laboratory (Webster, TX), as previously described (33) . The second batch included 307 case patients and 734 control subjects, using reagents from Millipore Corporation (Billerica, MA). Plasma proinsulin was measured in a single batch, using reagents from Millipore Corporation. Intact insulin assays were non-cross-reactive with proinsulin. The total proinsulin assay had 100% cross-reactivity with intact proinsulin and des-31,32 proinsulin, 81% cross-reactivity to des-64,65 proinsulin, and no crossreactivity with insulin. Blinded, randomly inserted samples from quality control plasma pools had mean intra-assay coefficients of variance of 2.0% for HbA1c, 5.4% for insulin, and 3.1% for proinsulin. For measurements below the limit of assay detection (less than 2 µIU/mL for insulin and less than 2 pM for proinsulin), participants were assigned 1 µIU/mL for insulin and 1 pM for proinsulin.
Plasma Samples
Statistical Analysis
To compare baseline characteristics, we used χ 2 test for categorical variables, paired t test for continuous variables, and nonparametric Wilcoxon signed-rank test for plasma markers, as they were not normally distributed. Partial Spearman correlation coefficients adjusted for batch, fasting status, and cohort were calculated for plasma markers and covariates. Quintiles of plasma insulin and proinsulin to insulin ratio were defined by batch (1/2) and fasting status (≥8 hours/<8 hours), based on levels in control subjects. Quintiles of plasma proinsulin were defined by fasting status (≥8 hours/<8 hours) based on levels in control subjects, as proinsulin was measured in a single batch. Quintiles of HbA1c were defined among all control subjects together, as fasting status is not relevant to HbA1c measurement (15) .
In primary analyses, we pooled participant-level data from quintile groups and computed odds ratios (ORs) to estimate relative risks and 95% confidence intervals [CIs] using unconditional logistic regression. We used unconditional regression because one of two control subjects was newly selected for 76 case patients from WHI. We also performed conditional logistic regression and metaanalysis of quintile groupings using a random effects model (34) , to confirm results with different analytic approaches. Tests for trend were calculated by entering pooled quintile-specific medians for the analyte as a continuous variable in regression models. We also evaluated a "global" trend test by including the log-transformed analyte as a continuous variable in regression models.
In our base model, we adjusted for matching factors. We evaluated covariates for confounding by adding each covariate in turn to the base model. No covariate changed the risk estimate by greater than 10%, including race, body mass index (BMI), multivitamin use, physical activity, alcohol, and total calories. As no strong confounders were identified, we included race and BMI in our multivariable-adjusted models, as in prior analyses (27, 33, 35) .
To evaluate whether subclinical malignancy influenced our results, we performed analyses with exclusion of case patients diagnosed within two, five, or 10 years of blood collection and their matched control subjects. We assessed heterogeneity across the five cohorts using Cochran's Q statistic (36) , which was 0.29, 0.38, 0.67, and 0.93 for HbA1c, insulin, proinsulin, and proinsulin to insulin ratio, respectively, for comparison of extreme quintiles. We also conducted a meta-analysis of individual study data, in which we calculated odds ratios for each cohort and then pooled the cohortspecific odds ratios to compute a summary risk estimate (34) . Given limited case patient and control subject numbers in individual cohorts, we evaluated collapsed quintiles 2-5 vs quintile 1 (referent) for HbA1c, and quintile 5 vs collapsed quintiles 1-4 (referent) for insulin, proinsulin, and proinsulin to insulin ratio.
In exploratory analyses, we evaluated associations of circulating markers with pancreatic cancer risk stratified by other predisposing factors, using the condensed quintiles. We assessed statistical interaction by entering main effect terms and a cross-product term of the binary analyte and stratification variable into the model, evaluating likelihood ratio tests. We also used receiver operating characteristic (ROC) curve analysis to calculate the area under the curve, known as the concordance statistic, for our base model and after addition of the circulating markers (37) . All statistical analyses were performed with the SAS 9.2 statistical package (SAS Institute). A P value of less than .05 was considered statistically significant. All P values are two-sided.
results
Characteristics of 449 pancreatic cancer case patients and 982 matched control subjects are shown in Table 1 and by cohort in Supplementary Table 1 (available online). Median levels of HbA1c, insulin, and proinsulin were higher in case patients than in control subjects, whereas the plasma proinsulin to insulin ratio was similar. Partial Spearman correlation coefficients among control subjects for BMI and circulating analytes were 0.14 for HbA1c, 0.36 for insulin, 0.43 for proinsulin, and -0.09 for proinsulin to insulin ratio (Supplementary Table 2 , available online).
Multivariable-adjusted global trend tests calculated by including the log-transformed circulating markers in pooled logistic regression models were .004 for HbA1c, less than .001 for insulin, and less than .001 for proinsulin (Table 2) For plasma proinsulin to insulin ratio, the multivariableadjusted global test for trend was .66 (Table 2 ). Compared to the bottom quintile, those in the top quintile had an OR of 1.03 (95% CI = 0.70 to 1.51). Similar non-statistically significant results were noted for conditional regression and meta-analysis of the quintile groupings.
The association between insulin, proinsulin, and pancreatic cancer risk became more pronounced after limiting inclusion to cases (and their matched controls) with greater time between blood collection and pancreatic cancer diagnosis (Table 3) , but were not statistically significant for HbA1c and the proinsulin to insulin ratio. Among case patients who developed cancer 10 or more years after blood collection and their matched control subjects, the fifth compared to first quintile had an OR of 2.77 (95% CI = 1.28 to 5.99; P trend = .004) for insulin and 3.60 (95% CI = 1.68 to 7.72; P trend < .001) for proinsulin.
For the four markers, results were similar across the five individual cohorts (Figure 1) . No statistically significant interactions of plasma insulin, proinsulin (Table 4) , HbA1c, or proinsulin to insulin ratio with pancreatic cancer risk were seen by sex, smoking status, BMI, physical activity, or fasting status.
Finally, we conducted a multivariable model with mutual adjustment for HbA1c, insulin, and proinsulin to assess the independent effects of these markers of hyperglycemia and insulin resistance. Following mutual adjustment, the association of pancreatic cancer risk with proinsulin remained strong, whereas the associations with HbA1c and insulin were no longer statistically significant (Table 5) . Comparing extreme quintiles in the mutually adjusted multivariate model, the OR was 1.30 (95% CI = 0.84 to 2.02; P trend = .66) for HbA1c, 0.93 (95% CI = 0.58 to 1.48; P trend = .69) for insulin, and 2.55 (95% CI = 1.54 to 4.21; P trend < .001) for proinsulin. ROC curve analysis also suggested that the discriminatory ability of our circulating markers was predominantly due to the addition of plasma proinsulin to our base model (Supplementary Table 3 , available online).
Discussion
In this pooled, nested case-control study from five large, prospective US cohorts, we noted statistically significant positive associations between risk of pancreatic cancer and prediagnostic circulating markers of hyperglycemia (HbA1c) and peripheral insulin resistance (plasma insulin and proinsulin). In contrast, the plasma proinsulin to insulin ratio, a marker of impaired β-cell function, was not associated with pancreatic cancer risk in our cohort participants. When evaluated in joint models, high levels of plasma proinsulin (a marker of peripheral insulin resistance) were associated with a nearly 2.5-fold increase in risk for pancreatic cancer, whereas HbA1c (a marker of hyperglycemia) was no longer associated with risk. Notably, the associations of plasma insulin and proinsulin with pancreatic cancer risk became progressively stronger after excluding patients diagnosed with pancreatic cancer within 5 or 10 years of their blood collection. Therefore, the likelihood is low that preclinical cancer led to alterations in peripheral insulin resistance, thereby explaining the observed associations.
Glucose intolerance has emerged as an important predisposing factor for pancreatic adenocarcinoma. Prospective studies have demonstrated an increased risk of pancreatic cancer with increasing BMI (3-5), a predisposing factor for hyperglycemia (10) . Although controversy remains regarding causation vs consequence (38) , diabetes mellitus has also been associated with pancreatic cancer risk in prospective studies (6) . Furthermore, prediagnostic fasting serum glucose and postload plasma glucose have been linked with the subsequent risk of pancreatic cancer (7) (8) (9) . Nevertheless, a number of mechanisms might underlie the higher risk of pancreatic cancer among individuals with impaired glucose processing, including the consequences of peripheral insulin resistance, impaired pancreatic β-cell function, and/or hyperglycemia itself (9) (10) (11) (12) .
Prospective studies have reported associations between pancreatic cancer risk and prediagnostic circulating levels of insulin and C-peptide, supporting the hypothesis that peripheral insulin resistance confers an increased risk for this malignancy (33, 39) . In <.001 * CI = confidence interval; HPFS = Health Professionals Follow-up Study; NHS = Nurses' Health Study; OR = odds ratio; PHS = Physicians' Health Study; WHI = Women's Health Initiative; WHS = Women's Health Study. † For the pancreatic cancer cases in the ≥2 years, ≥5 years, and ≥10 years groups, the median time between blood collection and pancreatic cancer diagnosis was 7.6 years, 9.3 years, and 13.5 years, respectively. ‡ Adjusted for prospective cohort (HPFS, NHS, PHS, WHI, WHS; which also adjusted for sex), smoking status (never, past, current <25 cigarettes/day, current ≥25 cigarettes/day, missing), fasting time (<4, 4-8, 8-12, ≥12 hours, missing) age at blood collection (continuous), race (white, black, other, missing) and body mass index (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m 2 ). § Test for trend calculated by entering quintile-specific median values for plasma marker as a continuous variable in logistic regression models. All P values were two-sided.
addition, a recent study with more limited follow-up time noted an elevated risk of pancreatic cancer with higher HbA1c values (9), highlighting the possible role of chronic hyperglycemia in promoting pancreatic tumorigenesis. In the current study with long median follow-up (12.2-25.3 years) and large case numbers with prediagnostic blood samples, we simultaneously measured circulating HbA1c, insulin, proinsulin, and proinsulin to insulin ratio to investigate hyperglycemia, insulin resistance, and impaired β-cell function in relation to pancreatic cancer risk.
HbA1c is a clinically relevant measure of chronic glucose exposure (15) . Circulating levels of insulin and proinsulin increase in the setting of peripheral insulin resistance, as higher insulin secretion is necessary to overcome reduced peripheral insulin signaling (10, 40, 41) . However, the proinsulin to insulin ratio is relatively stable in subjects with peripheral insulin resistance, as insulin and proinsulin levels rise largely in tandem. In contrast, β-cell dysfunction leads to impaired processing of proinsulin, with greater proinsulin in secretory granules and therefore a higher ratio of proinsulin to insulin in the circulation (17) (18) (19) . Therefore, the observed positive associations with insulin and proinsulin, but not the ratio, implicate peripheral insulin resistance rather than impaired β-cell function in the etiology of pancreatic adenocarcinoma. Furthermore, we observed that HbA1c was no longer statistically significantly associated with pancreatic cancer after adjustment for proinsulin, suggesting the importance of peripheral insulin resistance, rather than hyperglycemia, to pancreatic tumorigenesis. Peripheral insulin resistance is associated with alterations in multiple metabolic pathways, and additional research is necessary to better understand which pathways may underlie an increased risk of pancreatic cancer. Of note, proinsulin itself may impact cancer risk, as it has activity at the insulin receptor, with effects on cell proliferation (42, 43) , or may mark other systemic metabolic alterations not directly referable to states of insulin resistance.
The current study has a number of important strengths. Its prospective design and long follow-up time greatly reduced the likelihood of bias due to reverse causation and allowed a thorough evaluation of possible influences of preclinical disease. We excluded cases and controls with a history of diabetes at blood collection, minimizing the effects of clinical diabetes on insulin secretion and risk. Assays were performed in a single laboratory and blinded to identifiers of case patient and control subject status with excellent coefficients of variance for quality control samples. Our sample size was large for a prospective plasma study of pancreatic cancer, and cases were rigorously coded with confirmation by review of patient records. Covariate data were also rigorously collected, allowing for control of confounding and evaluation of effect modification.
Limitations of the current study included having a single measurement of circulating markers. However, studies with similar design have demonstrated associations between these markers and disease risk, suggesting that a single measurement is a reasonable proxy for longer-term exposure (15, 39, (44) (45) (46) * CI = confidence interval; HPFS = Health Professionals Follow-up Study; MET-h/wk = metabolic equivalent task-hours per week; NHS = Nurses' Health Study; OR = odds ratio; PHS = Physicians' Health Study; WHI = Women's Health Initiative; WHS = Women's Health Study. † Adjusted for prospective cohort (HPFS, NHS, PHS, WHI, WHS; which also adjusted for sex), smoking status (never, past, current <25 cigarettes/day, current ≥25 cigarettes/day, missing), fasting time (<4, 4-8, 8-12, ≥12 hours, missing) age at blood collection (continuous), race (white, black, other, missing) and body mass index (<18.5, 18.5-24.9, 25-29.9, ≥30 kg/m 2 ). ‡ P values for interaction were calculated by including a cross-product term of the binary analyte and stratification variable in the regression model and evaluating likelihood ratio tests. All P values were two-sided. § Stratified at the median of physical activity among control subjects.
dysfunction (16) (17) (18) (19) 47, 48) . We cannot rule out that our findings may be influenced in part by residual confounding. This may be more likely in analyses involving several cohorts, as not all covariates are collected identically. Nonetheless, the studies included in this analysis provided detailed information on known or suspected risk factors for pancreatic cancer and we evaluated multiple possible confounding covariates without observing meaningful changes in our risk estimates. Finally, our participants were predominantly individuals of European descent and further studies in other populations are warranted.
In sum, in this large, nested, prospective case-control study, we demonstrate that after mutual adjustment, markers of peripheral insulin resistance, rather than hyperglycemia or pancreatic β-cell dysfunction, are associated with risk of pancreatic adenocarcinoma. These findings provide important mechanistic insight into the established associations between obesity, type II diabetes mellitus, and pancreatic cancer risk. Furthermore, these findings underscore the value of correcting insulin resistance as a strategy for preventing this highly lethal malignancy.
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